Non Hodgkin Lymphoma Clinical Trial
In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET
Summary
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL).
Eligibility Criteria
Inclusion Criteria:
Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included:
Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to Lugano criteria
or
Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD)
MGUS/SMM or MM according to IMWG definitions
Age ≥18
Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards & Guidelines) from assays obtained <2 weeks prior to study enrollment/intervention; or negative urine pregnancy test performed on the day of intervention
MSKCC patients
Exclusion Criteria:
Breast-feeding
History of renal functional disorders (chronic kidney disease with eGFR<30)
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?